Name | Number of supported studies | Average coverage | |
---|---|---|---|
epithelial cell | 5 studies | 25% ± 8% | |
endothelial cell | 4 studies | 18% ± 2% | |
glutamatergic neuron | 4 studies | 32% ± 9% | |
GABAergic neuron | 3 studies | 25% ± 5% | |
astrocyte | 3 studies | 21% ± 6% | |
oligodendrocyte | 3 studies | 17% ± 2% | |
oligodendrocyte precursor cell | 3 studies | 22% ± 3% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 5 studies | 26% ± 7% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
bladder | 100% | 2871.76 | 21 / 21 | 100% | 84.46 | 504 / 504 |
breast | 100% | 3273.77 | 459 / 459 | 100% | 98.45 | 1118 / 1118 |
esophagus | 100% | 2938.92 | 1445 / 1445 | 100% | 88.69 | 183 / 183 |
intestine | 100% | 3222.80 | 966 / 966 | 100% | 98.52 | 527 / 527 |
liver | 100% | 2486.12 | 226 / 226 | 100% | 47.89 | 406 / 406 |
lung | 100% | 3819.51 | 578 / 578 | 100% | 84.96 | 1155 / 1155 |
ovary | 100% | 2984.94 | 180 / 180 | 100% | 72.43 | 430 / 430 |
prostate | 100% | 3358.69 | 245 / 245 | 100% | 72.22 | 502 / 502 |
skin | 100% | 3553.06 | 1809 / 1809 | 100% | 90.87 | 472 / 472 |
stomach | 100% | 2907.47 | 359 / 359 | 100% | 102.42 | 286 / 286 |
thymus | 100% | 4515.71 | 653 / 653 | 100% | 76.21 | 605 / 605 |
uterus | 100% | 3378.29 | 170 / 170 | 100% | 86.79 | 459 / 459 |
brain | 100% | 3180.05 | 2639 / 2642 | 100% | 101.61 | 705 / 705 |
kidney | 100% | 2780.25 | 89 / 89 | 100% | 55.67 | 898 / 901 |
adrenal gland | 100% | 3158.91 | 258 / 258 | 100% | 57.61 | 229 / 230 |
pancreas | 100% | 1947.46 | 328 / 328 | 99% | 74.62 | 177 / 178 |
adipose | 100% | 3191.93 | 1204 / 1204 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 65.26 | 29 / 29 |
muscle | 100% | 4024.00 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 3835.71 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 69.16 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 50.10 | 1 / 1 |
blood vessel | 100% | 2767.14 | 1334 / 1335 | 0% | 0 | 0 / 0 |
heart | 99% | 1924.89 | 856 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 99% | 51.53 | 79 / 80 |
peripheral blood | 94% | 1909.14 | 872 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0070925 | Biological process | organelle assembly |
GO_0002376 | Biological process | immune system process |
GO_0045948 | Biological process | positive regulation of translational initiation |
GO_0034063 | Biological process | stress granule assembly |
GO_1900271 | Biological process | regulation of long-term synaptic potentiation |
GO_0043488 | Biological process | regulation of mRNA stability |
GO_0007612 | Biological process | learning |
GO_0061157 | Biological process | mRNA destabilization |
GO_0002577 | Biological process | regulation of antigen processing and presentation |
GO_1902667 | Biological process | regulation of axon guidance |
GO_0045727 | Biological process | positive regulation of translation |
GO_0007613 | Biological process | memory |
GO_0000932 | Cellular component | P-body |
GO_0005737 | Cellular component | cytoplasm |
GO_0010494 | Cellular component | cytoplasmic stress granule |
GO_0043022 | Molecular function | ribosome binding |
GO_0003729 | Molecular function | mRNA binding |
GO_1990247 | Molecular function | N6-methyladenosine-containing RNA reader activity |
GO_0003723 | Molecular function | RNA binding |
GO_0005515 | Molecular function | protein binding |
Gene name | YTHDF1 |
Protein name | Alternative protein YTHDF1 YTH N6-methyladenosine RNA binding protein 1 YTH domain-containing family protein 1 (DF1) (Dermatomyositis associated with cancer putative autoantigen 1) (DACA-1) |
Synonyms | C20orf21 |
Description | FUNCTION: Specifically recognizes and binds N6-methyladenosine (m6A)-containing mRNAs, and regulates their stability . M6A is a modification present at internal sites of mRNAs and some non-coding RNAs and plays a role in mRNA stability and processing . Acts as a regulator of mRNA stability by promoting degradation of m6A-containing mRNAs via interaction with the CCR4-NOT complex . The YTHDF paralogs (YTHDF1, YTHDF2 and YTHDF3) shares m6A-containing mRNAs targets and act redundantly to mediate mRNA degradation and cellular differentiation . Required to facilitate learning and memory formation in the hippocampus by binding to m6A-containing neuronal mRNAs (By similarity). Acts as a regulator of axon guidance by binding to m6A-containing ROBO3 transcripts (By similarity). Acts as a negative regulator of antigen cross-presentation in myeloid dendritic cells (By similarity). In the context of tumorigenesis, negative regulation of antigen cross-presentation limits the anti-tumor response by reducing efficiency of tumor-antigen cross-presentation (By similarity). Promotes formation of phase-separated membraneless compartments, such as P-bodies or stress granules, by undergoing liquid-liquid phase separation upon binding to mRNAs containing multiple m6A-modified residues: polymethylated mRNAs act as a multivalent scaffold for the binding of YTHDF proteins, juxtaposing their disordered regions and thereby leading to phase separation . The resulting mRNA-YTHDF complexes then partition into different endogenous phase-separated membraneless compartments, such as P-bodies, stress granules or neuronal RNA granules . . |
Accessions | L8EA03 ENST00000370334.4 Q9BYJ9 ENST00000370339.8 [Q9BYJ9-1] Q5JXC6 |